Intuitive and Discreet Device Provides Sacral Neuromodulation Therapy for Overactive Bladder and Bowel Incontinence DUBLIN - December 17, 2018 - Medtronic plc (MDT) today announced U.S. Food and Drug ...
Medtronic reported that the FDA approved the InterStim smart programmer, an app-based platform that assists patients in the long-term management of therapy for overactive bladder or chronic fecal ...
The FDA has approved an app-based smart programming device used to discreetly and easily control implants treating for overactive bladder (OAB), chronic fecal incontinence (FI) and non-obstructive ...
San Francisco, CA USA (UroToday.com) -- Intuitive and Discreet Device Provides Sacral Neuromodulation Therapy for Overactive Bladder and Bowel Incontinence. Medtronic plc announced U.S. Food and Drug ...
DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...
Sacral neuromodulation is an advanced therapy for people with bladder and bowel control issues that are not responding to other non-invasive therapies. The system works by targeting nerve signals that ...
DUBLIN, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that its recently FDA-approved InterStim™ Micro neurostimulator for sacral ...
Medtronic continues to up its game in sacral neuromodulation. FDA approved InterStim X, the next generation of the company's InterStim portfolio's recharge-free device. Medtronic said implants have ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback